Source comparison
Tesamorelin + Ipamorelin Blend: Clinical Dosing vs Research Dosing Comparison
Starting Dose 200mcg tesamorelin + 200mcg ipamorelin daily 500mcg tesamorelin + 300mcg ipamorelin daily 100mcg tesamorelin + 100mcg ipamorelin daily Clinical titration reduces side effects and identifies individual sensitivity before escalating to therapeutic
This comparison does not assign a generated winner or score.
- Starting Dose
- 200mcg tesamorelin + 200mcg ipamorelin daily
- 500mcg tesamorelin + 300mcg ipamorelin daily
- 100mcg tesamorelin + 100mcg ipamorelin daily
- Clinical titration reduces side effects and identifies individual sensitivity before escalating to therapeutic dose
- Titration Duration
- 4 weeks with weekly dose increases
- No titration. Start at maintenance dose
- 6 weeks with biweekly increases
- Slow titration is essential for patients with unknown GH receptor density or prior GH therapy history
- Maintenance Dose
- 1mg tesamorelin + 200–300mcg ipamorelin
- 1.5–2mg tesamorelin + 300–500mcg ipamorelin
- 600–800mcg tesamorelin + 150–200mcg ipamorelin
- Maintenance dose must be adjusted based on IGF-1 response. Higher doses do not guarantee better outcomes and increase lipodystrophy risk
- Injection Frequency
- Once daily before bed
- Once daily, timing flexible
- Once daily before bed (strict timing)
- Pre-sleep injection on empty stomach is non-negotiable for mimicking endogenous GH pulse
- Monitoring Requirement
- IGF-1 serum test at weeks 6, 12, 24
- No monitoring specified
- IGF-1 + glucose + HbA1c at weeks 4, 8, 12
- High responders may develop hyperglycemia or insulin resistance. Monitoring prevents metabolic complications